AMG 386 Drug-Drug Interaction Study With Paclitaxel

• Status: Completed
• Trial end date: 2014-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the pharmacokinetics of paclitaxel when given alone and in combination with AMG 386 to determine whether AMG 386 alters the pharmacokinetics of paclitaxel

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Amgen
• Treatments: Albumin-Bound Paclitaxel; Paclitaxel; Trebananib

Criteria

Inclusion Criteria:

• Men or women ≥ 18 years of age

• Have a pathologically documented, and definitely diagnosed, advanced solid tumor that is refractory to standard treatment, or for which no curative therapy is available

• Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2

• Normal or clinically acceptable ECG (12 lead reporting PR, QRS, QTc)

Exclusion Criteria:

• Subjects with gastric cancer or any malignancy with purely squamous cell histology

• Known history of primary central nervous system (CNS) tumors or CNS metastases

• Myocardial infarction within 1 year before study day 1, unstable or uncontrolled disease/condition related to or affecting cardiac function

• History of stroke, arterial or venous thrombosis, or pulmonary embolism within 1 year before study day 1

• A baseline ECG QTc interval > 450 msec

• Active grade 2 or greater peripheral vascular disease

• History of pulmonary hemorrhage or gross hemoptysis within 6 months before study day 1

• Non-healing wound, ulcer (including gastrointestinal) or fracture

• Known positive test for human immunodeficiency virus infection, or active hepatitis B or hepatitis C infection

• Major surgery within 1 month before study day 1

• Concurrent antitumor treatment within 4 weeks (6 weeks for nitrosoureas or mitomycin) before study day 1

• Unable to tolerate IV administration or repeated blood withdrawal

• Hypersensitivity to paclitaxel or drugs using the vehicle cremophor

• Known sensitivity to mammalian-derived products, bacterially-produced proteins, or any of the products to be administered during dosing

• Chronic neuropathy grade ≥ 1

• Concurrent or prior treatment with 2C8 and 3A4 substrates

• Enrolled in or has not yet completed at least 30 days (prior to study day 1) since ending other investigational device or drug, or currently receiving other investigational treatment.

• Men and woman of reproductive potential, unwilling to practice a highly effective method of birth control for the duration of the study and an additional 6 months after the last dose of AMG 386

• Women who are lactating/breastfeeding

• Women with a positive pregnancy test

• Women planning to become pregnant during the duration of the study